Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIALL: Induction Therapy for Newly Diagnosed ALL/LLy/MPAL
NCT06289673Phase 4Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Dec 2024
- Primary completion
- May 2034
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dexamethasone, vincristine sulfate liposome injection, daunorubicin, methotrexate, cytarabine in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), mixed phenotype acute leukemia (MPAL), sponsored by St. Jude Children's Research Hospital. Started Dec 2024; status: recruiting.
02
Drugs
dexamethasonevincristine sulfate liposome injectiondaunorubicinmethotrexatecytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT06289673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289673.